摘要
With the aging of society, dementia has become a more and more serious social problem. Alzhei-mer’s disease （AD） is a major cause of dementia, and there is no drug to reverse the disease progression. Donepezil is the main drug currently in symptomatic treatment. How-ever,the effcacy of donepezil was moderate, with the patient variably responding to the treatment with donepe-zil. The commonest adverse events in the treatment were nausea,vomiting,and diarrhea; QT prolongation rarely occurred. Many patients gave up treatment because of adverseevents orlack of effcacy. Pharmacogenomicsis developed on the basis of pharmacogenetics, by studying the polymorphisms in genes involved in drug metabolicenzymes, transporter and drug receptor, to guide individ-ualized treatment. In terms of the pharmacogenomics on the effcacyof onepezil, there is no clear conclusion ex-cept CYP2D6 genotype affecting drug clearance.
